volume 9, issue 9, P5508-5516 2020
DOI: 10.21037/tcr-20-1512a
View full text
|
|
Share

Abstract: Background: Programmed death ligand-1 (PD-L1) has been identified as an established biomarker for predicting response to immunotherapy in a variety types of cancer. However, the clinicopathological and prognostic significance of this protein in small cell lung cancer (SCLC) patients remains controversial.Methods: Eligible studies extracted from the databases of PubMed, MEDLINE, Embase, and CNKI databases were evaluated. Statistical analysis was performed using STATA 11.2 software.Results: A total of 483 PD-L1+…

expand abstract